The weekly litigation news digest is live. Subscribe now

IP Verse

Pharmaceutical Composition Containing Rifaximin Alpha&Delta - EP3294270

The patent EP3294270 was granted to Sandoz on Sep 12, 2018. The application was filed on Mar 22, 2017 under application number EP17712970A. The patent is currently recorded with a legal status of "Revoked".

EP3294270

SANDOZ
Application Number
EP17712970A
Filing Date
Mar 22, 2017
Status
Revoked
Feb 14, 2024
Publication Date
Sep 12, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
ALFASIGMAJun 12, 2019KRAUS & LEDERER PARTGMBBADMISSIBLE
ALFRED E TIEFENBACHERJun 12, 2019HAMM & WITTKOPPADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTEP1698630
INTERNATIONAL-SEARCH-REPORTUS9018225
OPPOSITIONEP1557421
OPPOSITIONEP1698630
OPPOSITIONEP2927235
OPPOSITIONWO2005044823
OPPOSITIONWO2017162726

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents